A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)

Arthritis, Juvenile Rheumatoid Clinical Trial

Official title:
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension 0.25mg/kg and 0.125 mg/kg Administered Once Daily in Comparison to Naproxen Oral Suspension 5mg/kg Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis.

Status Completed

Clinical Trial Summary

A one year double-blind trial to investigate the efficacy and safety of meloxicam oral suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral suspension 5 mg/kg administered twice daily in children with Juvenile Rheumatoid Arthritis.

Clinical Trial Description

Objective: In an international, multicenter, double-blind, randomized clinical trial we evaluated the short-term (3 months) and long term (12 months) efficacy and safety of two doses of meloxicam oral suspension compared with naproxen in children with oligo and polyarticular course juvenile idiopathic arthritis (JIA).

Methods: Children with active oligo or polyarticular course JIA, requiring therapy with an NSAID were eligible for this trial. Patients were randomly allocated to therapy with meloxicam oral suspension 0.125 mg/kg body weight in single daily dose, meloxicam 0.25 mg/kg body weight in single daily dose, or naproxen 10 mg/kg body weight in two daily doses. The trial drugs were administered in a double-blind, double-dummy design for up to 12 months. Response rates were determined according to the American College of Rheumatology Pediatric 30% definition of improvement (ACR Ped 30). Safety parameters were assessed by evaluation of the adverse events in the 3 groups.

Study Hypothesis:

The null hypothesis of interest is that the magnitude of response with regard to the primary endpoint is equivalent between the treatment groups. The alternative is that there is any difference (two-sided) between any of the treatment groups.

Comparison(s):

Naproxen oral suspension 10 mg/kg body weight. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00279747
Study type	Interventional
Source	Boehringer Ingelheim
Contact
Status	Completed
Phase	Phase 3
Start date	September 2000
Completion date	January 2003

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00807846` - A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects	Phase 4
Completed	`NCT00652925` - A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA	Phase 3
Completed	`NCT02001844` - Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA	N/A
Completed	`NCT00731965` - Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis	Phase 4
Completed	`NCT02067962` - Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing	N/A
Terminated	`NCT00868751` - Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis	N/A
Terminated	`NCT00637780` - Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis	Phase 4
Completed	`NCT00001614` - The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis	Phase 1
Completed	`NCT01412021` - Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
Enrolling by invitation	`NCT02377245` - Juvenile Inflammatory Rheumatism (JIR) Cohorte
Completed	`NCT00426218` - Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)	Phase 1/Phase 2
Completed	`NCT00034853` - Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)	Phase 3
Completed	`NCT06000566` - Drug Compliance and Affecting Factors in Juvenile Idiopathic Arthritis
Terminated	`NCT00511329` - Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease	Phase 2/Phase 3
Terminated	`NCT00688545` - Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
Recruiting	`NCT00012506` - The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.